title: Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.
authors.affiliation: Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
authors.forename: Alex
authors.initials: A
authors.lastname: Thompson
authors.affiliation: Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia.
authors.forename: Stephen
authors.initials: S
authors.lastname: Locarnini
authors.affiliation: Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: Revill
mesh_terms: D000998:Antiviral Agents; D004279:DNA, Viral; D005838:Genotype; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic; D006801:Humans
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens
keywords: ANTIVIRAL THERAPY; GENOTYPE; HEPATITIS B; MUTATIONS